X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (58) 58
index medicus (50) 50
chemotherapy (37) 37
male (37) 37
oncology (37) 37
female (36) 36
aged (35) 35
lung neoplasms - drug therapy (32) 32
middle aged (32) 32
carcinoma, non-small-cell lung - drug therapy (30) 30
cancer (28) 28
lung cancer, non-small cell (25) 25
lung cancer (24) 24
carcinoma, non-small-cell lung - pathology (23) 23
adult (21) 21
lung neoplasms - pathology (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
respiratory system (19) 19
life sciences (18) 18
erlotinib (17) 17
neoplasm staging (16) 16
carcinoma, non-small-cell lung - mortality (15) 15
treatment outcome (15) 15
aged, 80 and over (14) 14
lung neoplasms - mortality (14) 14
non-small cell lung cancer (14) 14
non-small-cell lung cancer (14) 14
care and treatment (13) 13
docetaxel (13) 13
lung neoplasms (13) 13
pulmonary/respiratory (13) 13
antineoplastic agents - therapeutic use (12) 12
carcinoma, non-small-cell lung - economics (12) 12
cisplatin - administration & dosage (12) 12
disease-free survival (12) 12
lung neoplasms - economics (12) 12
research (12) 12
santé publique et épidémiologie (12) 12
analysis (11) 11
hematology, oncology and palliative medicine (11) 11
trial (11) 11
deoxycytidine - analogs & derivatives (10) 10
erlotinib hydrochloride (10) 10
lung neoplasms - genetics (10) 10
prospective studies (10) 10
carcinoma, non-small-cell lung (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
carcinoma, non-small-cell lung - therapy (9) 9
cisplatin (9) 9
cost-benefit analysis (9) 9
cost-effectiveness (9) 9
deoxycytidine - administration & dosage (9) 9
france (9) 9
gemcitabine (9) 9
lung neoplasms - therapy (9) 9
metastasis (9) 9
mutation (9) 9
oncology, experimental (9) 9
pemetrexed (9) 9
prognosis (9) 9
survival (9) 9
survival analysis (9) 9
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (8) 8
bevacizumab (8) 8
guanine - analogs & derivatives (8) 8
mesh : humans (8) 8
mesh : lung neoplasms (8) 8
quinazolines - therapeutic use (8) 8
receptor, epidermal growth factor - genetics (8) 8
therapy (8) 8
antineoplastic agents (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - economics (7) 7
development and progression (7) 7
economic aspects (7) 7
gefitinib (7) 7
kaplan-meier estimate (7) 7
medicine & public health (7) 7
mesh : carcinoma, non-small-cell lung (7) 7
nsclc (7) 7
phase-iii (7) 7
protein kinase inhibitors - therapeutic use (7) 7
surgery (7) 7
vinorelbine (7) 7
1st-line treatment (6) 6
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (6) 6
antineoplastic combined chemotherapy protocols (6) 6
brca1 (6) 6
cancer therapies (6) 6
cell lung-cancer (6) 6
cost analysis (6) 6
cost of illness (6) 6
economics (6) 6
follow-up studies (6) 6
france - epidemiology (6) 6
medicine (6) 6
open-label (6) 6
prevalence (6) 6
quality of life (6) 6
quinazolines - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Expert review of pharmacoeconomics & outcomes research, 10/2018, Volume 18, Issue 5, p. 519
Journal Article
Journal Article
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 33, pp. 4050 - 4051
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 09/2014, Volume 20, Issue 17, pp. 4647 - 4659
Journal Article
Expert Review of Pharmacoeconomics and Outcomes Research, ISSN 1473-7167, 09/2018, Volume 18, Issue 5, pp. 519 - 528
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2012, Volume 12, Issue 1, pp. 301 - 301
Journal Article
Lung Cancer, ISSN 0169-5002, 07/2018, Volume 121, pp. 25 - 29
Journal Article
Journal Article
ClinicoEconomics and Outcomes Research, ISSN 1178-6981, 2012, Volume 4, Issue 1, pp. 269 - 275
First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall... 
Cost-benefit analysis | Nonsmall cell lung cancer | Erlotinib | Europe | Epidermal growth factor receptor | Wild-type | Economic aspects | Development and progression | Epidermal growth factor | Lung cancer, Non-small cell | Analysis | Cost analysis | Lung cancer | Metastasis
Journal Article